Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis

Blood Cells Mol Dis. 2016 Sep:60:74-7. doi: 10.1016/j.bcmd.2016.03.003. Epub 2016 Mar 8.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amino Acid Substitution
  • Calreticulin / genetics*
  • Calreticulin / metabolism
  • Female
  • Humans
  • Janus Kinase 2 / genetics*
  • Janus Kinase 2 / metabolism
  • Male
  • Middle Aged
  • Mutation, Missense*
  • Primary Myelofibrosis* / blood
  • Primary Myelofibrosis* / genetics
  • Primary Myelofibrosis* / pathology
  • Thrombocythemia, Essential* / blood
  • Thrombocythemia, Essential* / genetics
  • Thrombocythemia, Essential* / pathology

Substances

  • CALR protein, human
  • Calreticulin
  • JAK2 protein, human
  • Janus Kinase 2